An LLM platform lets epilepsy patients text with their EEG device
Retraining the seizure detector on patient feedback alone cut false alarms by 77–81% in a pseudoprospective simulation
UPDATED WEEKLY
Frontier biomedicine and deals, every week
From breakthrough paper to licensing deal. Weekly briefs on the research reshaping drug discovery, and the deals and conferences where it changes hands.
Opens your email app with a pre-filled request; we add you by hand. Free, unsubscribe any time.
THIS WEEK'S LEAD · AI DRUG DESIGN
An LLM platform lets epilepsy patients text with their EEG device; in a simulation, their replies cut false seizure alarms by about 80%
In 13 inpatients at Penn's epilepsy monitoring unit, a chatbot linked to live scalp or intracranial EEG answered questions, sent seizure and sleep alerts and collected feedback; in a pseudoprospective simulation, retraining the detector on that feedback alone cut false alarms by 77–81% without losing sensitivity. Live sessions used only the baseline detector.
Oct 13, 2026 · Source: Nature MedicineRead the analysis →
Latest science
All science →
FJ-0125 blocks IL-18 and IL-4Rα and outperforms dupilumab in a dermatitis mouse model
Fusing IL-18BP to a humanized anti-IL-4Rα antibody suppressed type 1, 2 and 3 inflammation more broadly than dupilumab or IL-18BP-Fc
CD19 CAR-engineered Tregs promote durable tolerance in lupus models
A CD19 CAR plus constitutive FOXP3 turns CD4 T cells into regulatory cells that both deplete B cells and suppress autoimmunity
Restoring IL-15 signalling boosts innate immunity in brain metastasis
The brain starves innate lymphoid cells of IL-15; restoring it locally lets them control metastasis without T cells
TEM1657 suppresses NFKBIZ and eases psoriasis-like inflammation in mice
A plant-derived small molecule tunes mitochondrial dynamics to switch off the NFKBIZ program that drives psoriatic inflammation
MedGemma brings open medical vision-language models to Gemma 3
One open-weight model family, medically tuned from Gemma 3, spanning medical images and text
Shotgun engineering rebuilds amino acid synthesis in CHO and Jurkat cells
Barcoded constructs delivered at high multiplicity turn each cell into its own pathway experiment
In vivo BCMA CAR-T phase 1: 15 months of follow-up, one ongoing sCR
Green CAR-T cells attacking a red myeloma cell at right
Briefs
3 items · based on abstracts
-
In vivo LNP delivery generates CAR-NK cells
Nature Biotechnology · Oct 13, 2026 · doi:10.1038/s41587-026-03310-1 Correspondence: Daniel G. Anderson (MIT)The authors built NK cell-targeted lipid nanoparticles using engineered biparatopic NK cell ligands for receptor-specific uptake and mRNA delivery, reaching up to about 80% NK cell transfection in mice with minimal off-target effects. Systemic delivery of chimeric antigen receptor mRNA generated CAR-NK cells in vivo: CD19-targeted CAR-NKs completely depleted circulating B cells in healthy mice, and CD3-targeted CAR-NKs eliminated nearly all autoreactive T cells in an autoimmune hepatitis model. In solid tumors, nanoparticles targeting the inhibitory checkpoint NKG2A enhanced antitumor efficacy by relieving Qa-1b-mediated immunosuppression, and optimized particles enabled regression of two humanized hematologic malignancy models.
基于摘要 / Based on abstract · Generated: -
D2C7 antibody-toxin conjugate: a phase 1 trial in recurrent glioma
Nature Medicine · Oct 16, 2026 · doi:10.1038/s41591-026-04715-w Correspondence: Vidyalakshmi Chandramohan (Duke University Medical Center)D2C7-ATC is a recombinant antibody-toxin conjugate targeting wild-type EGFR and EGFRvIII. In a single-arm, single-site, open-label phase 1 trial (NCT02303678), 81 patients with biopsy-confirmed recurrent malignant glioma received one infusion by convection-enhanced delivery. Median overall survival was 7.9 months among the 72 patients with IDH wild-type recurrent glioblastoma; the recommended phase 2 dose was 6,920 ng/ml, and the maximum tolerated dose was exceeded at 35,032 ng/ml where four patients had dose-limiting toxicities. Treatment-related adverse events were mainly grade 1-2 (67%); eight patients died on trial, all unrelated to D2C7-ATC. In univariate analyses, patients with IDH wild-type recurrent glioblastoma whose pre-treatment tumour D2C7 antibody reactivity score was below 1.5+ had a median overall survival of 17.38 months.
基于摘要 / Based on abstract · Generated: -
Why TCR antigen specificity prediction fails to generalise: a preprint perspective
bioRxiv · Oct 18, 2026 · doi:10.64898/2026.10.12.758456 Correspondence: Hashem Koohy (University of Oxford)This preprint perspective asks why increasingly sophisticated models of TCR antigen specificity, from small neural networks to deep generative models and large protein language models, largely fail in independent benchmarks to generalise to TCRs or pMHCs absent from development data. Analysing the largest public TCR:pMHC repositories, the authors report significant biases towards a few antigens and MHC molecules, sparse sampling of TCR sequence space per pMHC, and inconsistent or inaccurate data collation. They argue evaluations must measure antigen-specific discrimination rather than confounders, and that metrics should match the downstream application.
Preprint perspective · 基于摘要 / Based on abstract · Generated:
China out-licensing tracker
Annual tally →157deals in 2025
$135.7Btotal value, 2025
~5%paid upfront ($7.0B)
Bar length = total deal value; dark segment = combined upfront payments. Data: DIA Global Forum, March 2026. Most of the headline value is milestones that are paid only if development succeeds. Every deal we track, with sources →
Latest deals & data
All deals →
Estuary Bio raises $103M to advance local AAV therapy for ADPKD
$103M total
AstraZeneca and insitro form a strategic collaboration in difficult-to-treat cardiometabolic disease
$40M upfront
OMass Therapeutics raises a $310M Series C
$310M (GBP230M)
City Therapeutics prices upsized IPO at about $200M
About $200M
Upcoming conferences
All events →Oct 18–20, 202623rd DIA Japan Annual Meeting 2026Tokyo, Japan · RegulatoryOct 18–21, 2026ISPE Annual Meeting & Expo 2026Washington, DC area, USA · Manufacturing & CMCOct 22–24, 202664th Annual Meeting of the Japan Society of Clinical Oncology (JSCO 2026)Kobe, Japan · ScientificOct 23–27, 2026ESMO Congress 2026Madrid, Spain · ScientificOct 26–29, 2026AMCP Nexus 2026San Diego, CA, USA · Market Access & HEOROct 27–29, 2026AI Drug Discovery & Development Summit 2026Boston, MA, USA · Digital Health & AINov 2–4, 2026BioCentury-BayHelix China Healthcare Summit (13th)Shanghai, China · PartneringNov 4–8, 2026SITC 2026 Annual MeetingPhoenix, AZ, USA · ScientificNov 5–9, 2026AASLD The Liver Meeting 2026Denver, CO, USA · Scientific
Working on an asset or a landscape report? See Services →
One email a week
New science briefs and cross-border licensing & M&A deals, each with a link to the original source. Free; unsubscribe any time.
Sources cited in our briefs. Science: Nature ×13, Nature Portfolio ×18, Cell Press ×2, bioRxiv ×6, Taylor & Francis ×1, JCI ×1, Company of Biologists ×1, NEJM ×1. Deals: BioPharma Dive ×4, AllSci ×3, Fierce Biotech ×3, BioSpace ×2, BioPharm International ×1, BioXconomy ×1, DIA Global Forum ×1, HKEXnews ×7, SEC EDGAR ×2, PR Newswire ×6, GlobeNewswire ×2, Business Wire ×1, Company press releases ×12. Counts = briefs or citations per source; every item links to its original.